Drugs / istiratumab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02538627 | Aug 2015 → Oct 2016 | colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Merrimack Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01733004 | Nov 2012 → Jan 2016 | hepatocellular carcinoma | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02399137 | May 2015 → Aug 2018 | malignant pancreatic neoplasm | Merrimack Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | istiratumab | “Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line...” PMID 31912800 ↗ Jan 2020 |
| Known as | MM-005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989990 ↗ |
| Known as | MM-141 | “Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line...” PMID 31912800 ↗ Jan 2020 |
| Action | Inhibit | “dual blockade of the insulin-like growth factor-1 receptor (IGF-1R) and HER3 pathways” PMID 31912800 ↗ Jan 20201“Receptor tyrosine-protein kinase erbB-3 inhibitor” CHEMBL3989990 ↗ |
| Modality | Monoclonal antibody | “istiratumab, an IGF-1R- and ErbB3-bispecific antibody” PMID 31912800 ↗ Jan 2020 |
| Route | Intravenous | “2.8 g intravenously (i.v.) every 2 weeks” PMID 31912800 ↗ Jan 2020 |
| Target | ERBB3 | “Receptor tyrosine-protein kinase erbB-3 inhibitor” CHEMBL3989990 ↗ |
| Target | IGF1R | “dual blockade of the insulin-like growth factor-1 receptor (IGF-1R) and HER3 pathways” PMID 31912800 ↗ Jan 2020 |